» Articles » PMID: 31139324

Gender Differences in Cancer Risk After Kidney Transplantation

Overview
Journal Oncotarget
Specialty Oncology
Date 2019 May 30
PMID 31139324
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Kidney transplant (KT) recipients are at greater risk of developing some cancers than the general population. Moreover, cancer is the only cause of death that is currently increasing after kidney transplantation. We analyzed incidence, risk factors and characteristics of post-transplant malignancies (solid organ tumors and lymphoproliferative disorders) at our center in 925 KT recipients (1979-2014). Sex differences were particularly assessed. One hundred and eight patients (11.7%) developed solid organ tumors (76.9%) or lymphoma (23.1%). Twenty-one percent of patients who reached 20 years after KT developed cancer, with a median post-KT time to diagnosis of 7.4 years. Most common solid organs affected were lung (30.1%), prostate (10.8%), bladder (9.6%), and native kidney (7.2%). When analyzing standardized incidence ratios (SIR) by gender compared to the general population, relative risk was increased in women (SIR = 1.81; 95%CI, 1.28-2.45) but not significantly increased in men (SIR = 1.22; 0.95-2.52). Regarding specific types, gynecological (SIR = 11.6; 4.2-22.7) and lung (SIR = 10.0; 4.3-18.2) in women, and bladder (SIR = 16.3; 5.9-32.1) in men were the most affected locations. Thymoglobulin, a polyclonal antibody that has been used as an immunosuppressive agent in kidney transplantation over the last decades, was a significant risk factor for developing cancer in adjusted regression analysis [IRR = 1.62, 1.02-2.57; p = 0.041], and was associated with lower patient survival. Compared with the general population, the incidence of post-KT non-skin cancer is almost two-fold higher in women but not significantly higher in men. Lung is the most common solid organ affected. Thymoglobulin induction therapy is associated with a greater risk.

Citing Articles

Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation.

Jayanti S, Beruni N, Chui J, Deng D, Liang A, Chong A Cochrane Database Syst Rev. 2024; 12:CD014966.

PMID: 39698949 PMC: 11656698. DOI: 10.1002/14651858.CD014966.pub2.


Increased risk of genitourinary cancer in kidney transplant recipients: a large-scale national cohort study and its clinical implications.

Kim H, Chae K, Choi A, Kim M, Hong J, Choi B Int Urol Nephrol. 2024; 57(3):715-722.

PMID: 39443429 PMC: 11821677. DOI: 10.1007/s11255-024-04244-w.


Gender and kidney transplantation.

Nautiyal A, Bagchi S, Bansal S Front Nephrol. 2024; 4:1360856.

PMID: 38711923 PMC: 11070561. DOI: 10.3389/fneph.2024.1360856.


Chronic kidney diseases and the risk of colorectal cancer: A systematic review and meta-analysis.

Al-Qudimat A, Al Darwish M, Altahtamouni S, Singh K, Al-Zoubi R, Aboumarzouk O Arab J Urol. 2024; 21(4):258-266.

PMID: 38178950 PMC: 10763595. DOI: 10.1080/2090598X.2023.2225315.


Sex differences in cancer incidence among solid organ transplant recipients.

Jackson S, Pfeiffer R, Hsieh M, Li J, Madeleine M, Pawlish K J Natl Cancer Inst. 2023; 116(3):401-407.

PMID: 37944040 PMC: 10919340. DOI: 10.1093/jnci/djad224.


References
1.
Wong G, Chapman J, Craig J . Death from cancer: a sobering truth for patients with kidney transplants. Kidney Int. 2014; 85(6):1262-4. DOI: 10.1038/ki.2013.494. View

2.
Hall E, Engels E, Pfeiffer R, Segev D . Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2014; 99(5):1051-7. PMC: 4405385. DOI: 10.1097/TP.0000000000000449. View

3.
Kao C, Liu J, Lin M, Hsu C, Chang F, Lin Y . Impact of mTOR Inhibitors on Cancer Development in Kidney Transplantation Recipients: A Population-Based Study. Transplant Proc. 2016; 48(3):900-4. DOI: 10.1016/j.transproceed.2016.01.017. View

4.
Campistol J, Eris J, Oberbauer R, Friend P, Hutchison B, Morales J . Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006; 17(2):581-9. DOI: 10.1681/ASN.2005090993. View

5.
Alberu J, Pascoe M, Campistol J, Schena F, Del Carmen Rial M, Polinsky M . Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011; 92(3):303-10. DOI: 10.1097/TP.0b013e3182247ae2. View